ClinConnect ClinConnect Logo
Search / Trial NCT02920060

Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus

Launched by BANARAS HINDU UNIVERSITY · Sep 28, 2016

Trial Information

Current as of May 28, 2025

Completed

Keywords

Rse

ClinConnect Summary

In our study patients were considered to have RSE if children were still having active convulsions despite receiving injection lorazepam intravenously at a dose of 0.1 mg/kg (max 4 mg) at a rate maximum upto 2 mg/min or intravenous diazepam at a dose of 0.2 - 0.3 mg/Kg (maximum 10 mg) slowly or intravenous midazolam at a dose of 0.15 - 0.2 mg/kg(max 5 mg). In case of children with difficult intravenous access buccal/nasal midazolam 0.2 - 0.3 mg/kg (maximum 5 mg) per rectal diazepam 0.5 mg/kg (maximum 10 mg) or intramuscular midazolam 0.2 mg/kg (maximum 5 mg). If seizure continued at 5 minut...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age - 1 year to 16 years
  • 2. Gender - male and female both
  • 3. Refractory generalized convulsive status epilepticus i.e. not responding to any two of the first line drugs
  • Exclusion Criteria:
  • 1. Patients with epilepsia partialis continua.
  • 2. Patients with definite history of any allergic reaction to intravenous levetiracetam or intravenous valproate, or any contraindications in giving these drugs.

About Banaras Hindu University

Banaras Hindu University (BHU) is a prestigious institution located in Varanasi, India, renowned for its commitment to excellence in education and research across various disciplines, including medicine and health sciences. As a clinical trial sponsor, BHU leverages its robust academic infrastructure and multidisciplinary expertise to advance innovative research aimed at improving healthcare outcomes. The university fosters collaboration between researchers, healthcare professionals, and community stakeholders to ensure the ethical conduct and scientific rigor of its clinical trials, ultimately contributing to the advancement of medical knowledge and the development of effective therapeutic interventions.

Locations

Patients applied

0 patients applied

Trial Officials

Rajniti Prasad, MD

Study Director

Banaras Hindu University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials